BPA for xphozah (TENAPUNOR)
Active Awarded Last action
- Contract number
- 36E79724A0015
- Awardee
-
Ardelyx, Inc. UEI YLYTCEN9K617
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 84% complete
- IDV ceiling
- $32,500,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Ardelyx, Inc., a pharmaceutical company headquartered in Fremont, California, has been awarded a $32.5 million Blanket Purchase Agreement (BPA) by the National Acquisition Center under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB). The BPA was awarded on April 30, 2024, with an ultimate completion date of April 29, 2027, and represents a single-award, non-set-aside contract. Under this IDV, Ardelyx supplies XPHOZAH (tenapanor), a specialized medication indicated for the treatment of hyperphosphatemia in patients undergoing dialysis. The contract supports the Department of Veterans Affairs' clinical mission to address chronic kidney disease and associated electrolyte management needs within the veteran population. The BPA serves as the parent vehicle enabling Department of Veterans Affairs medical centers nationwide to issue firm fixed-price delivery orders for XPHOZAH 30 milligram tablets, with individual delivery orders historically ranging from approximately $2,000 to $16,000 per order.
Performance under the BPA is distributed across multiple Veterans Integrated Service Networks, including VISN 5, VISN 9, VISN 12, VISN 20, and VISN 21, with supporting operations conducted across geographic locations including Tennessee, Ohio, and California. The contract establishes Ardelyx as the primary supplier of XPHOZAH within the VA healthcare system, enabling efficient procurement and distribution of this specialized pharmaceutical to veterans with dialysis-dependent chronic kidney disease. The BPA incorporates 2026 public law pricing updates and provides the Department of Veterans Affairs with the flexibility to respond to routine supply replenishment and emergency pharmaceutical requests across its integrated service networks.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79724A0015?
36E79724A0015 was awarded to Ardelyx, Inc. by National Acquisition Center (Headquarters) on April 30, 2024.
How much is contract 36E79724A0015 worth?
36E79724A0015's own ceiling is $32,500,000.
Who can order from contract 36E79724A0015?
36E79724A0015 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79724A0015 under another contract?
Yes. 36E79724A0015 is a blanket purchase agreement under 36F79722D0165, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79724A0015 competed?
The extent of competition for 36E79724A0015 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV